While autoimmune diseases with autoantibody driven pathology mechanisms appear to be amenable to therapeutic intervention by BTK inhibitors, correlation of autoantibody threshold levels to clinical efficacy has not been published or well established in these studies. Here, BTK is linked to autoimmune disease.